Genmab's Third Quarter 2026 Financial Results - ADC THERAPEUTICS SA

Financial Performance:

• Total revenue for the first nine months of 2026 increased 22% year-over-year, reaching a projected full-year range of $4.325 billion to $4.525 billion (19% growth at midpoint).
• Revenue growth was broad-based: Darzalex grew 19%, Apkinley (global net product sales) surged 47% to $491 million, and the remainder of the portfolio increased 30%.
• Adjusted operating profit rose 9% year-over-year, with full-year guidance maintained at a range of $1.065 billion to $1.35 billion, likely ending above the $1.2 billion midpoint.
• Operating expenses (OPEX) are projected between $2.81 billion and $2.95 billion (midpoint ~$2.88 billion); Q4 OPEX will step up significantly due to manufacturing, clinical development, and launch readiness activities.
• Effective tax rate for the first nine months was 3.4%, expected to normalize over the next 12–18 months following the integration of Maris.
• Company maintains financial discipline with a commitment to deleverage to below 3x gross leverage by the end of 2027.

Guidance and Future Outlook:

• Maintains 2026 financial guidance; revenue expected in the upper part of the range due to strong Apkinley momentum and royalty portfolio growth.
• Confident in delivering strong profitability in 2026 and continued growth in 2027, with 2027 consensus OPEX expectations considered reasonable.
• Peak sales targets maintained for three key late-stage assets: >$3 billion for Apkinley, >$2 billion for Renas, and multi-billion for Pitocentumab.
• Anticipates potential launches for Apkinley (first-line DLBCL), Renas (ovarian/endometrial), and Pitocentumab (head and neck) in 2027.
• Pipeline expansion includes moving four new antibody-based programs (two bispecifics, two ADCs) into the clinic this year, with two more expected by year-end.

Business Segments and Product Lines:

• Apkinley (Bispecific Antibody): Sales of $491 million (first nine months); most prescribed bispecific in lymphoma globally. Phase 3 APPEAR-DLBCL trial showed PFS hazard ratio of 0.49 in first-line diffuse large B-cell lymphoma (DLBCL), potentially becoming a standard of care. Uptake accelerating in US community settings and Japan; second-line FL launch successful.
• Renas (Antibody-Drug Conjugate): Phase 3 RAINFALL-02 trial met primary (PFS HR 0.29) and secondary (OS) endpoints in platinum-resistant ovarian cancer. Approved/reimbursed in recurrent cervical cancer; program expanding to endometrial cancers.
• Pitocentumab (ADC): Phase 3 LIGA-HN1 trial met dual endpoints (OS HR 0.5, ORR) in first-line head and neck cancer (HNSCC), the first positive Phase 3 in nearly a decade. Phase 3 trials also active in second/third-line settings and colorectal cancer (CRC).
• Tibdac: Sales of $131 million (first nine months), up 9% YoY, driven by growth in US and new markets in Japan and Europe.
• Commercialization: Building a scalable engine for 2027 launches; expanding site activation and physician networks, particularly in community care settings.

Market and Competitive Landscape:

• Apkinley's Phase 3 data (HR 0.49) described as unprecedented in DLBCL over the last 25 years, positioning it to potentially replace R-CHOP as the new standard.
• Differentiation vs. competitors (e.g., Polaris/Polizumab for Apkinley; Amivantamab for Pitocentumab) highlighted by superior safety profiles, subcutaneous administration capabilities, and dual indications facilitating community treatment.
• Strong momentum in Japan and Europe for existing products; expanding reimbursement and access for Tibdac to support future Renas and Pitocentumab launches.
• Competitive pressure noted in head and neck and colorectal cancers, but GenMap emphasizes unmet medical needs and differentiation via safety/tolerability.

Risks and Challenges:

• Clinical Readouts: While Phase 3 results have been positive, final OS data for Apkinley (APPEAR-DLBCL) is considered immature with short follow-up (10 months), though confidence remains high that benefits will persist.
• Safety Events: A slight increase in Grade 5 deaths noted in Apkinley trials, described as multifactorial with no new isolated safety signals.
• Regulatory Strategy: Renas filing strategy in endometrial cancer may pivot to rely on the Phase 3 randomized trial rather than single-arm data due to SACT-T&T competition.
• Expirations: Royalty stream from Darzalex will eventually expire (late 2020s), though management asserts building blocks are in place to sustain growth.
• Investment Costs: Significant Q4 OPEX increases required for launch readiness and clinical development could impact short-term cash flow, though offset by revenue growth.

Management Commentary and Tone:

• Tone was highly confident and energized, describing the year as "landmark" and "unprecedented" regarding Phase 3 readouts.
• Management emphasized "sustained financial growth," "high-potential late-stage pipeline," and "disciplined capital allocation" as the three core themes.
• Leadership expressed strong conviction that the combination of broad revenue diversification and high-quality data allows for continued investment without sacrificing profitability.
• Repeated emphasis on execution capabilities, commercial infrastructure readiness, and the "high-conviction" nature of the data driving peak sales estimates.

Analyst Questions and Answers:

• Apkinley Safety/OS: CMO Tai Yamadi clarified that OS hazard ratio is based on immature data (10-month follow-up) but expects improvement; deaths are multifactorial, not COVID-related. Frontline data likely serves as confirmatory for regulatory approval.
• Peak Sales Confidence: CFO Anthony Pagano and COO Brad Bailey reaffirmed >$3B for Apkinley, >$2B for Renas, and multi-billion for Pitocentumab, citing strong data and commercial capabilities.
• Treatment Duration (Pitocentumab): CMO noted that durability in CRC is driven by mechanism and safety profile, with second-line data informing first-line expectations; safety profile is distinct from competitors (Amivantamab).
• Subcutaneous Formulation: Development of subcutaneous versions for Apkinley and Pitocentumab is ongoing (partnerships/ACI) as lifecycle management, but specific timelines and bridging study details were not disclosed.
• BD Strategy: CEO Jan van de Winkel confirmed active business development for combinations but prioritized maximizing internal late-stage assets; organic pipeline expansion continues with 4 new programs moved to clinic.
• Colorectal Opportunity: Management views CRC as a larger potential opportunity than head and neck due to higher unmet need, with early Phase 2 data showing strong response rates in KRAS Wild-type patients.

Other Key Points:

• Upcoming events include an annual virtual R&D update and ASH data review on December 16, featuring over 20 accepted abstracts with six oral presentations.
• Renas program is expanding into a broad Phase 3 portfolio across ovarian and endometrial cancers, aiming to be the "best, first, and broadest" in class in gynecologic oncology.
• Apkinley is being positioned to treat patients in community settings due to differentiated dual indication and subcutaneous potential, addressing care access barriers.
• The company is actively planning engagement with health authorities for potential filing of Renas based on existing Phase 3 results.